Key result
Beta-caryophyllene pretreatment significantly reduced doxorubicin-induced ST-segment elevation (0.19 mV vs 0.37 mV, p<0.001) and improved cardiac, hepatic, and renal oxidative stress biomarkers in rats.
Why the study?
Doxorubicin causes dose-dependent cardiomyopathy, congestive heart failure, and hepato-renal toxicity, prompting investigation into whether beta-caryophyllene can protect against doxorubicin-induced multiple organ toxicity.
Does beta-caryophyllene prevent doxorubicin-induced multiple organ toxicity in rats?
Does beta-caryophyllene prevent doxorubicin-induced multiple organ toxicity in rats?
Absolute Event Rate: 0.19% vs 0.37%
p-value: p=<0.001
Beta-caryophyllene demonstrates protective effects against doxorubicin-induced cardiotoxicity, hepatotoxicity, and nephrotoxicity in a rat model by reducing oxidative stress.
Beta-caryophyllene may attenuate doxorubicin toxicity in rats; hypothesis-generating and should not yet change clinical practice.
The major limiting factor in doxorubicin’s long-term administration is the development of cumulative dosedependent cardiomyopathy and congestive heart failure. Also, doxorubicin causes deterioration in hepato-renal function. It significantly increases the levels of blood urea nitrogen, creatinine, alanine transaminase, and aspartate transaminase distortion in normal renal and hepatic histology. The present study was undertaken to find out the protective role of beta-caryophyllene (BCP), an anti-oxidant against doxorubicin-induced multiple organ toxicities in experimental animals. In this study, male Wistar rats were divided into four groups. The first group, control group, was administered with vehicle (2.5% tween 20); the second group received doxorubicin (15 mg/kg intraperitoneally at a single dose), third and fourth groups (treatment groups) received BCP plus doxorubicin (15 mg/kg) at doses of 100 mg/kg and 200 mg/kg respectively. BCP was given orally for 15 days and doxorubicin was given on 13th day of treatment. Cardiac function was assessed by measuring electrocardiogram changes and cardiac biomarkers—doxorubicin-induced significant lengthening of QT-interval and ST-elevation, which was completely prevented by BCP treatment. Doxorubicin caused oxidative stress as indicated by a significant decrease in reduced superoxide dismutase, glutathione level, and catalase activity with an increase in malondialdehyde compared to control. Doxorubicin and BCP significantly reversed these values compared to doxorubicin in heart, kidney, and liver. The histopathological examination has also shown signs of toxicity in doxorubicin treated groups, and healing effect was noticed in treatment groups.
No takes yet. Share an insight, caveat, or question.
Veleti et al. (2020) studied Doxorubicin-induced multiple organ toxicity (n=24). Beta-caryophyllene vs. Doxorubicin alone was evaluated on ST segment elevation (mV) (p=<0.001). Beta-caryophyllene pretreatment significantly reduced doxorubicin-induced ST-segment elevation (0.19 mV vs 0.37 mV, p<0.001) and improved cardiac, hepatic, and renal oxidative stress biomarkers in rats.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: